Complete response to induction therapy is associated with significant 82% decreased odds of death at 12 months.
In a nationwide study, renal transplant recipients with lupus nephritis had a 70% lower risk for all-cause mortality than nonrecipients.
Using electrochemiluminescence, researchers found 5 urinary proteins that have “reasonable specificity” for lupus nephritis.
Researchers observed comparable long-term outcomes between patients with late- and early-onset lupus nephritis.
Researchers identified SERPINA3 as a potential urine biomarker to quantify lupus nephritis.
Over a 5-year period, the drug was well tolerated and associated with significant declines in urinary protein-creatinine ratio and mean prednisolone dose.
Death from lupus ranked 10th in women 15 to 24 years, 14th in those aged 25 to 34 and 35 to 44 years.
In a phase 2b trial, around half of patients taking the novel calcineurin inhibitor at a dose of 23.7 mg twice daily achieved complete remission at 48 weeks.
End-stage renal disease is 5-fold more likely to develop in patients with 3 or more infection-related hospitalizations versus none.
The primary outcome was reduction in proteinuria, as measured by protein-to-creatinine (P:C) ratio in a 12-hour urine collection, at 24 weeks compared with baseline.